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GSK3βIn this study we investigated the effect of HPV16 E6 on the Wnt/β-catenin oncogenic signaling pathway.
Luciferase reporter assays indicated that ectopically expressed E6 signiﬁcantly augmented the Wnt/β-
catenin/TCF-dependent signaling response in a dose-dependent manner. This activity was independent of
the ability of E6 to target p53 for degradation or bind to the PDZ-containing E6 targets. Epistasis experiments
suggested that the stimulatory effect is independent of GSK3β or APC. Coexpression, half-life determination,
cell fractionation and immunoﬂuorescence analyses indicated that E6 did not alter the expression levels,
stability or cellular distribution of β-catenin. Further experiments using E6 mutants defective for E6AP
binding and E6AP knockdown cells indicated the absolute requirement of the ubiquitin ligase E6AP for
enhancement of the Wnt signal by E6. Thus, this study suggests a role for the E6/E6AP complex in
augmentation of the Wnt signaling pathway which may contribute to HPV induced carcinogenesis.
© 2009 Elsevier Inc. All rights reserved.Introduction
Infection of the anogenital mucosa with papillomavirus types
referred to a “high risk” or oncogenic such as HPV16 and HPV18 is a
major factor for the subsequent development of cancer (Zur-Hausen,
1996, 2002). HPV infection of the basal epithelium perturbs cell
differentiation and enhances cell proliferation. Two oncoproteins are
encoded by the oncogenic HPVs, E6 and E7, which are invariably
expressed in HPV-positive cervical cancers and cancer-derived cell
lines (Zur-Hausen, 1996, 2002; Narisawa-Saito and Kiyono, 2007). E6
and E7 contribute to the oncogenic process, at least in part, through
their ability to interact with cellular tumor suppressor proteins and
inactivate their functions. E7 associates with the tumor suppressor
pRb and other cell cycle regulatory proteins that control cell cycle
progression, whereas the E6 oncoprotein primarily associates with
proteins participating in the control of genome stability or signaling
pathways that involve cell–cell interactions and cytoskeleton organi-
zation (reviewed in Narisawa-Saito and Kiyono, 2007; Mammas et al.,
2008; McLaughlin-Drubin and Munger, 2009; Howie et al., 2009). E6
is also responsible for transcriptional activation of the telomerase
reverse transcriptase (TERT) gene which is the catalytic subunit of the
enzyme telomerase (reviewed in Howie et al., 2009).
The Wnt signaling pathway plays an important role in the
development of several types of cancer, particularly colorectal cancer).
ll rights reserved.(CRC; reviewed in Polakis, 2000; Lustig and Behrens, 2003; Giles et al.,
2003; Kikuchi, 2003; Clevers, 2006). Abnormalities in the canonical
Wnt/β-catenin pathway lead to tumor formation. The canonical Wnt
signal pathway is controlled by two major regulatory multiprotein
complexes; theβ-catenin “destruction complex” that controls the level
of β-catenin, a key effector protein of the canonical Wnt pathway, and
the TCF transcription complex, comprised of various corepressors and
coactivators, which controls the level of the TCF transcriptional activity
(reviewed in Polakis, 2000; Lustig and Behrens, 2003; Giles et al., 2003;
Kikuchi, 2003; Clevers, 2006; Mosimann et al., 2009;Willert and Jones,
2006). In the absence of Wnt signaling, intracellular β-catenin levels
are regulated by amultiprotein complex encompassing kinases, such as
the glycogen synthase kinase-3β (GSK3β) and casein kinase 1 and 2
(CK1 and 2), and the scaffolding proteins adenomatous polyposis coli
(APC), Axin1 and Axin2 (conductin). This “destruction complex” binds
and phosphorylates β-catenin at serine and threonine residues, thus
targeting it for ubiquitination and proteolytic degradation. In the
presence of Wnt ligands, coactivation of the Frizzled and LRP (low-
density lipoprotein receptor-related proteins) receptors leads to
inhibition of the destruction complex and the consequent stabilization
of β-catenin. Intracellular β-catenin accumulation eventually results in
its nuclear translocation where it binds to members of the TCF/LEF
family of transcription factors, alters the association of TCF with
corepressors such asGroucho/TLE andCtBP, interactswith coactivators
such as the histone acetylase CBP and chromatin remodeling proteins
such as Brg1, and activates transcription of various genes including
cyclin D1, MYC, TCF-1 and others.
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the β-catenin, APC, and Axin genes have been frequently found in
several human cancers leading to stabilization and accumulation of β-
catenin and increase of TCF-mediated gene expression (Lustig and
Behrens, 2003; Giles et al., 2003; Kikuchi, 2003; Clevers, 2006). In
addition to the canonicalWnt signal-mediated β-catenin stabilization,
β-catenin expression is regulated also by other pathways via GSK3β-
dependent or -independent mechanism (Liu et al., 2001; Matsuzawa
and Reed, 2001; Sadot et al., 2001; Xiao et al., 2003; Nastasi et al.,
2004; Sharma et al., 2004; Bachar-Dahan et al., 2006).
Several of the cellular targets of HPV E6 oncoproteins were
associated with pathways acting in the control of β-catenin stability
or activity including hDlg, hScrib, p53 and p300/CBP (reviewed in
Mammas et al., 2008; Howie et al., 2009). Dlg binds to the carboxy-
end of APC in a region shown previously to be required for the tumor
suppressing activity of APC (Matsumine et al., 1996) and APC–hDlg
complexes were shown to be important for the negative regulation of
cell cycle progression (Ishidate et al., 2000; Matsumine et al., 1996).
Human Scribble also interacts with APC (Takizawa et al., 2006). The
tumor suppressor p53was linked to both phosphorylation-dependent
and -independent pathways that mediate β-catenin degradation (Liu
et al., 2001; Matsuzawa and Reed 2001; Sadot et al., 2001), apparently
through its ability to activate transcription of APC and Siah-1, whereas
CBP/p300 were shown to act as bimodal regulators of Wnt signaling
(Li et al., 2007).
The role of Wnt pathway in the development of cervical cancer is
unknown, although recent reports provide evidence for a possible
link. Mutations in β-catenin gene were found to be uncommon in
cervical carcinoma (Ueda et al., 2001; Shinohara, 2001; Su et al.,
2003), however abnormal expression of β-catenin was reported in
several studies. Immunochemistry analysis of cervical tumors showed
the accumulation of β-cateninwithin the cytoplasm and/or nuclei in a
high percentage of these tumors (Shinohara et al., 2001; Pereira-
Suarez et al., 2002; Rodriguez-Sastre et al., 2005; Uren et al., 2005).
Abnormal β-catenin immunoreactivity was associated with advanced
pathologic stages of adenocarcinoma (Imura et al., 2001) and changes
in cadherins and β-catenin expression were shown to be associated
with progression of squamous intraepithelial lesions in the cervical
uterine (Rodriguez-Sastre et al., 2005; Uren et al., 2005). Microarray
expression studies conducted on cervical cancer tissues identiﬁed
alterations in the expression of positive and negative regulators of the
Wnt signaling pathway (Shim et al., 1998; Perez-Pereira et al., 2007).
As HPV E6 oncoprotein interacts with several components acting in
the Wnt–β-catenin pathway we hypothesized that E6 might affect
Wnt signaling. To this end, we investigated the effect of HPV16 E6
expression on a β-catenin/TCF-dependent luciferase-based reporter.
We present evidence that HPV16 E6 is able to augmentβ-catenin/TCF-
dependent transcription induced by Wnt3a or β-catenin expression.
We show that E6mediated enhancement of β-catenin/TCF signaling is
independent of GSK3β activity and phosphorylation of β-catenin and
is not associated with major alterations in the levels, stability or
cellular distribution of β-catenin. We also demonstrate that augmen-
tation of TCF/β-catenin transcription by E6 is independent of the
ability of E6 to target p53 and PDZ-containing proteins. However, it
depends on the expression of the E3-ubiquitin ligase E6AP and ability
of E6 to associate with E6AP, as well as on the activity of the pro-
teasome system.
Results
Wnt-induced β-catenin/TCF-dependent transcription is enhanced by the
E6 oncoprotein
The canonical Wnt signaling results in the stabilization of β-
catenin, which forms active transcriptional regulation complexes with
members of the TCF/LEF transcription factors. A well-establishedfunctional assay of Wnt signaling makes use of TCF-dependent
luciferase reporter constructs containing several copies of the TCF-
binding sites (TOPFLASH) or mutated TCF-binding sites (FOPFLASH)
that is used as control (Korinek et al., 1997). The effect of HPV16 E6 on
the canonical Wnt pathway was ﬁrst examined in transient co-
expression assays using HEK293T cells. Ectopic expression of E6 alone
failed to induce a TCF-dependent signaling response (data not
shown). However, addition of Wnt3a condition medium (CM;
Fig. 1A) or coexpression of E6 with Wnt3a and HFz1 (human Frizzled
1; Fig. 1B–D) resulted in a dose-dependent enhancement of the
Wnt3a-induced response reaching up to 5-fold. The stimulatory effect
of E6 was also evident on a native TCF-responsive promoter, the cyclin
D1 promoter, a Wnt target gene containing the TCF-binding domain
within its transcriptional unit (Shtutman et al., 1999; Fig. 1B). E6 also
caused a moderate elevation of the endogenous levels of cyclin D1
protein in addition to the elevation in the reporter activity (data not
shown). Both, the native, wild-type HPV16 E6 and the AU1 epitope-
tagged E6, stimulated the β-catenin/TCF-dependent transcription
whereas HPV16 E7 caused no enhancement and even reduced β-
catenin/TCF transcription (Fig. 1C). The speciﬁcity of the E6 effect on
TCF-dependent transcriptionwas demonstrated by theminimal signal
readouts induced by the control plasmid superFOPFLASH (0.001–0.01
of superTOPFLASH; data not shown) and further conﬁrmed by
coexpression of a dominant-negative TCF4 protein that resulted in
downregulation of the Wnt induced signal both in the vector and E6
transfected cells (Fig. 1D). Induction of Wnt signaling and augmen-
tation by HPV16 E6 could be also demonstrated in other cells, besides
HEK293T, including HEK293 that lack the SV40 T antigen, Madin-
Darby, canine kidney (MDCK) cells (data not shown) and human
C33A cervical carcinoma cells (Fig. 1E). Luciferase readouts in extracts
of C33A cells were lower than in HEK293T, however, either transient
transfection of E6 (Fig. 1E) or stable transduction of E6 (data not
shown) augmented the TCF-dependent luciferase reporter activity.
Consistent with the effect of HPV16 E6 on TCF-dependent transcrip-
tion, elevated cyclin D levels were detected in several cervical
carcinoma cell lines containing HPV including SiHa, CaSki and HeLa
as compared to C33A that lack HPV (Fig. 2).
To determine whether E6 proteins of low-risk HPV types also
enhance β-catenin/TCF transcription, we examined the activities of
E6 proteins from high risk, HPV16 and HPV18, versus low risk, HPV11,
in the luciferase reporter assay. The results (Fig. 1F) indicated that
HPV16 E6 and to a lower extent, HPV18 E6, were capable of
augmenting the TCF-luciferase reporter activity whereas HPV11 E6
only minimally enhanced luciferase activity. Hence, these studies
demonstrate distinction in the ability of high and low risk HPV types
to augment theWnt signal as well as difference among high risk types,
with HPV16 E6 being more potent than HPV18.
HPV16 E6 enhancement of β-catenin/TCF transcription is independent of
p53 and the PDZ containing E6 targets
A well-known target of the high-risk E6s is p53. E6 could possibly
mediate its stimulatory activity through p53 inactivation. Activity of
the tumor suppressor p53was linked to both pathways that regulateβ-
catenin destruction, the phosphorylation-dependent GSK3β-mediated
pathway (Sadot et al., 2001) and the phosphorylation-independent
pathway mediated by Siah-1 (Liu et al., 2001; Matsuzawa and Reed,
2001). Elimination of p53 by E6 could theoretically lead to inhibition of
β-catenin degradation resulting in increased cytoplasmic pools of β-
catenin leading to activation of TCF/LEF-mediated transcription. To
evaluate whether E6 effect is mediated by inactivation of p53, we
compared the ability of a series of HPV16 E6 mutants to enhance TCF-
dependent transcription and degrade p53. In addition, we tested the
ability of HPV16 E6 to augment TCF/LEF activity in cells that lack p53.
Analysis of a set of previously characterized E6mutants (Sherman et al.,
2002) indicated that a truncated E6 protein lacking 10 amino acids
Fig. 1. β-Catenin/TCF-dependent transcriptional response is enhanced by the E6 oncoprotein. (A) HEK293T cells were transfected with the TCF-luciferase reporter superTOPFLASH
(TOP) or the mutated TCF reporter superFOPFLASH (FOP), β-gal, and increasing amounts of the HPV16 E6 DNA as indicated. Wnt signal was induced by treating the cells withWnt3a
CM 24 h after transfection. (B) HEK293T cells were cotransfected with the Cyclin D luciferase reporter and β-gal, Wnt signal was induced by cotransfection of the HFz1 and Wnt3a
plasmids. (C) HEK293T cells were cotransfected with Wnt3a and HFz1, the TOP/FOP luciferase reporter, β-gal and increasing amounts of the HPV16 E6, E6A or E7 DNA as indicated.
(D) HEK293T cells were cotransfected as in C and in addition with a dominant negative TCF encoding plasmid (0.1 μg). (E) C33A cells were cotransfected with Wnt3a and HFz1, the
TOP/FOP and Renilla luciferase reporters, and increasing amounts of the 16E6 DNA. (F) HEK293T cells were transfected with the TOP/FOP luciferase reporter, β-gal and two amounts
of the 16E6, 18E6 or 11E6 plasmid DNA. Cells were treated with Wnt3a CM to induce the signal. In all reporter assays luciferase activity was determined 48 h after transfection The
readouts obtained with the mutated TCF luciferase reporter (FOP; not shown, extremely low) were subtracted from the readouts obtained with the TOP reporter. Data are presented
as fold activation (readouts obtained in the E6 expressing cells relative to the readouts in the vector expressing cells which were presented as 1). Fold activation values obtained by
E6 or E7 from three to ﬁve independent experiments (mean±SD) are shown. The increases in signal (fold activation) induced by E6 (0.1–2.5 μg) are statistically signiﬁcant (Pb0.05).
49H. Lichtig et al. / Virology 396 (2010) 47–58from the carboxy-terminus (M141) was active in stimulation of
transcription and even induced higher levels of transcription, whereas
the E6 truncation mutant lacking 19 amino acids (M132) failed to
stimulate Wnt3a-induced β-catenin/TCF transcription (Fig. 3A).Fig. 2. Cyclin D protein levels in different cervical carcinoma cell lines. Western blot
analysis of cyclin D protein levels in cell lysates from the indicated cervical carcinoma
cell lines (100 μg). Tubulin was used as a loading control.Similarly, mutants containing small deletions within the putative
carboxy-terminal zinc-ﬁnger failed to enhance Wnt/TCF transcription
whereas mutant G136C containing substitution of glycine in place of
cysteine in amino acid 136 exhibited reduced activity (Fig. 3A). These
results suggested that integrity of the zinc-ﬁnger structure may
possibly be necessary for the E6 stimulatory function in Wnt/TCF
transcription. The results also indicated that the ability of E6 to
augment Wnt/TCF signaling is independent of its p53 degradation
activity (Fig. 3B). Supporting this conclusion is the fact that mutant
d118-122, previously demonstrated (Sherman et al., 2002) and in this
study (Fig. 3B) to be active in p53 degradation, was unable to stimulate
TCF transcription. Furthermore, E6 also enhanced TCF-dependent
transcription in the lung carcinoma H1299 cell line lacking p53
(Fig. 3C). These ﬁndings were further conﬁrmed by the enhancing
effect of E6 on the Wnt signal induced in C33A cervical cancer cells
(Fig. 1E and data not shown), SW480 and colo320 colon carcinoma cell
lines (described below), all containing mutated p53, as well as in
HEK293T cells which lack a functional p53 protein. These results also
indicated that enhancement of the β-catenin/TCF transcription is not
mediated via binding of E6 to the PDZ motives in the PDZ-containing
partners (reviewed in Mammas et al., 2008; Howie et al., 2009), as
Fig. 3. Abilities of HPV16 E6 mutants to enhance TCF/β-catenin-dependent transcription and induce p53 degradation. (A) HEK293T cells were cotransfected with the TOP/FOP
luciferase reporter, β-gal and HPV16 E6 ormutant plasmid (0.5 μg), as indicated. Wnt signal was induced by cotransfection of HFz1 andWnt3a. Luciferase activity was determined 48
h posttransfection. Fold activity, average and SD, from at least three assays are shown. (B) H1299 cells were transfected with the plasmids encoding p53 (1 μg), HPV16 E6 or mutant
E6 (0.5 μg) and GFP (0.5 μg). Total cell lysates were prepared 48 h after transfection and levels of residual p53 were determined in a Western blot assay. (C) H1299 cells were
transfected with DNA of the TOP/FOP and Renilla luciferase reporters together with the indicated amounts of the 16E6 DNA.Wnt signal was induced by addition of Wnt3a CM to the
cells 24 h after transfection. Data of fold activation from three assays (mean±SD) are shown.
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β-catenin/TCF transcription. This effect of M141 was exhibited in
assays where Wnt signal was induced by Wnt3a and HFz1, Wnt3a CM
or wild-type β-catenin (Fig. 3A and data not shown).
Enhancement of the TCF/β-catenin signal by HPV16 E6 does not depend
on the APC/Axin/GSK3β complex
Cellular β-catenin levels are tightly controlled mainly by the APC/
GSK3 β/Axin complex (the β-catenin degradation complex). E6
protein could possibly enhance the Wnt signal by interfering with the
action of the β-catenin degradation complex. To test this possibility,
we evaluated the effect of HPV16 E6 in cells where the activity of
GSK3β was inhibited and in cells containing a mutated APC or β-
catenin protein in which the Wnt signal is constitutively activated.
Treatment of HEK293T cells with LiCl, an inhibitor of GSK3β, induced
high signaling response that was further enhanced by ectopic
expression of E6 in a dose-dependent manner. Fold enhancement
by E6 was comparable to that obtained in cells where Wnt signaling
was induced by transfection of the Wnt3a/HFz-1 plasmids (Fig. 4A).Fig. 4. E6 enhancement of the Wnt signal is independent from the β-catenin degradation co
and DNA of the TOP/FOP and β-gal reporters. Cells were either treated with LiCl or cotransfec
h after transfection. Average and SD of fold activation from three experiments are shown. (C
DNA of the TOP/FOP and Renilla reporter plasmids. Luciferase activity wasmeasured 48 h aftE6 also enhanced TCF transcription in SW480 cells containing mutant
APC protein that is deﬁcient in its ability to promote β-catenin
degradation (Munemitsu et al., 1995; Fig. 4B). Similar results were
obtained in coexpression assays using colo320 colon carcinoma cells
that contain a different APC mutant (Rosin-Arbesfeld et al., 2003; Fig.
4C). These results indicated that E6 enhancement of TCF/β-catenin-
dependent transcription is independent of GSK3β or APC.
Furthermore, we tested the effect of HPV16 E6 on the transcrip-
tional response induced by a mutant β-catenin, S33Y, that is relatively
refractory to GSK3β mediated phosphorylation and hence to β-TrCP
degradation (Hart et al., 1999). Results showed that the signal induced
by the mutant β-catenin was higher than the signal induced by the
wild type β-catenin, however, the enhancement of transcription by E6
was at comparable levels (Fig. 5A). Consistent with this result,
expression of E6 in a colon carcinoma cell line containing mutant β-
catenin with deletion of serine 45 (HCT116; Morin et al., 1997)
enhanced β-catenin/TCF transcription (Fig. 5B). Taken together, these
results indicate that E6-mediated enhancement of β-catenin/TCF-
dependent transcription is independent of the APC/GSK3β/Axin
complex activity.mplex. (A) HEK293T cells were transfected with increasing amounts of HPV16 E6 DNA
ted withWnt3a and HFz1 to induce theWnt signal. Luciferase activity was measured 48
, D) The indicated cells were transfected with increasing amounts of HPV16 E6 DNA and
er transfection. Data of fold activation from at least three assays (mean±SD) are shown.
Fig. 5. TCF-dependent transcriptional response induced by mutant β-catenin is
enhanced by HPV16 E6. (A) HEK293T cells were cotransfected with wt or mutant
(S33Y) β-catenin DNA (1 μg), increasing amounts of the 16E6 DNA and DNAs of the
TOP/FOP luciferase and β-gal reporters. Luciferase activities were measured 48 h after
transfection. Average and SD of luciferase activity from three experiments are shown.
(B) HCT116 cells were transfected with the TOP/FOP and Renilla luciferase reporters
together with the indicated amounts of HPV16 E6. Luciferase activity was evaluated
48 h after transfection. Average and SD of fold activation from three experiments are
shown.
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of β-catenin
Cellular β-catenin levels are also controlled by other mechanisms,
via GSK3β-dependent or -independent mechanism (Liu et al., 2001;
Matsuzawa and Reed, 2001; Sadot et al., 2001; Xiao et al., 2003;
Nastasi et al., 2004; Sharma et al., 2004; Bachar-Dahan et al., 2006)
and therefore we examined whether the activity of E6 is mediated by
changes in β-catenin expression levels or stability. Initially, weFig. 6. HPV16 E6 does not alter the level or stability of the total or active pool of endogenic
amounts of HPV16 E6. At 48 h after transfection cells were harvested and β-catenin levels
against β-catenin and unphosphorylated (active) β-catenin. Tubulin was used for loading co
the TOP/FOP luciferase plasmids. (C) HEK293T cells were transfected with the 16E6 express
added. Cells were harvested at the indicated time points. Equal protein samples of total cell l
is shown. (D) Western blot analysis of β-catenin protein levels in the indicated cervical carci
loading control.determined the effect of ectopic expression of E6 on levels of β-
catenin in HEK293T cells. As HEK293T cells are efﬁciently transfected,
we expected to be able to detect the effect of the transfected E6 on the
endogenous levels of β-catenin. In these experiments we used
antibodies detecting all forms of β-catenin or a speciﬁc antibody
which binds to the unphosphorylated N-terminus of β-catenin, thus
recognizing the active pool of the protein (Hendriksen et al., 2005).
Western blot analyses revealed no signiﬁcant changes in levels of the
total or active cellular β-catenin in cells where β-catenin/TCF
transcription was enhanced by HPV16 E6 in a dose-dependent
manner (Fig. 6A, B). Similar results were obtained in additional
experiments where levels of endogenous or exogenous β-catenin
were examined including HEK293T cells transfected with the GFP-
16E6 expression vector, C33A cells stably transduced with 16E6 or
HEK293T cells cotransfected with E6 and a GFP-β-catenin expression
plasmid (data not shown).
Next, the ability of HPV16 E6 to alter β-catenin stability was
assessed using half-life determination assays. The degradation rate of
β-catenin following cycloheximide (80 μg/ml) addition was deter-
mined in E6/vector transfected HEK293T cells. The results indicated
that levels of β-catenin gradually decreased following cycloheximide
addition with similar rates in E6 and vector cells. After 4 h, β-catenin
levels were reduced to about 70% both in E6 and vector transfected
cells (Fig. 6C). Similar results were obtained in experiments where
ectopically expressed GFP-β-catenin was coexpressed with E6 or
vector. At 6 h, there was a 50% reduction in the ectopically expressed
GFP-β-catenin with no signiﬁcant variation between the E6 and
vector transfected cells (data not shown). These data suggested that
HPV16 E6 protein does not signiﬁcantly alter the expression levels or
stability of β-catenin. Consistent with these data, no major differences
in the levels of β-catenin were observed between HPV-positive and
HPV-negative carcinoma cell lines (Fig. 6D).β-catenin. (A) HEK293T cells were cotransfected with Wnt3a and HFz1 and increasing
were measured in the total cell lysates by Western blot assay using speciﬁc antibodies
ntrol. (B) Luciferase reporter activity was measured in the same cells by transfection of
ion plasmid (5 μg) or vector. At 48 h after transfection, cycloheximide (80 μg /ml) was
ysates (100 μg) were analyzed by SDS-PAGE and immunoblotting. A representative blot
noma cell lines. 100 μg protein from total cell lysates was analyzed. Actin was used as a
Fig. 7. HPV16 E6 does not alter the cytoplasmic or nuclear distribution of β-catenin. HEK293T cells were transfected with increasing amounts of E6. Wnt signal was induced by
transfection of Wnt3a and HFz1. At 48 h after transfection the soluble cytoplasmic (A) or nuclear (B) fractions were isolated and levels of β-catenin or active β-catenin were
evaluated by Western blot analysis. Representative blots and densitometric scans from the cytoplasmic (A) and nuclear (B) fractions are shown.
Fig. 8. β-Catenin localization in HPV16 GFP-E6 expressing cells. HCT116 cells were transiently transfected with plasmids encoding the GFP-16E6 or GFP using the jetPEI transfection
reagent. At 48 h posttransfection, cells were subjected to immunoﬂuorescence analysis with the anti-β-catenin antibody. The cells were also stained with DAPI to visualize nuclei
(blue color in overlay image, right panels). Cells were visualized by confocal microscopy (A). The percentage of cells showing week or strong staining of β-catenin in the membrane
or nuclei is shown in B (at least 30 transfected cells were analyzed in each slide).
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The canonical Wnt signal is induced when unphosphorylated β-
catenin accumulates in the cytoplasm and translocates to the nucleus.
Thus, E6 could have possibly enhanced transcription by speciﬁcally
increasing the soluble cytoplasmic or nuclear pool of β-catenin. The
effect of E6 on cellular distribution of β-catenin was evaluated by cell
fractionation and immunoﬂuoresence. HPV16 E6 was transfected into
HEK293T and 48 h posttransfection cells were fractionated and
subcellular distribution of the endogenous β-catenin was analyzed by
Western blot. Levels of cytoplasmic or nuclear β-catenin were
determined relative to compartment speciﬁc protein markers, tubulin
and histone, respectively (Fig. 7A, B). Transfection of the Wnt3a and
HFz1 encoding plasmids causedmoderate increase in β-catenin levels.
However, no difference in the levels of β-catenin could be observed in
the soluble (phosphorylated and nonphosphorylated; Fig. 7A) or
nuclear (Fig. 7B) fractions between cells transfected with E6 or empty
vector. In the same cells, enhancement of the Wnt signal by E6 was
clearly indicated in the reporter assay (data not shown). Similar
results were obtained in cells treated with the Wnt3a CM (data no
shown). The effect of E6 on cellular localization of β-catenin was
further investigated employing immunoﬂuorescence analyses using
the HPV16 GFP-tagged E6 protein (GFP-16E6) and the GFP expression
vector as a control. The endogenous β-catenin was detected by
immunohistochemistry. HCT116 cells transfected with GFP-16E6
showed strong nuclear staining of E6 with less intensity in the
cytoplasm, unlike cells transfected with the GFP vector that showed
strong GFP staining throughout the cell (Fig. 8A). These results
indicated that E6 promoted the nuclear localization of GFP. In bothFig. 9. Enhancement of the Wnt signal by HPV16 E6 is E6AP dependent. (A) U2OS cells exp
Cells were cotransfected with Wnt3A, HFz1, the TOP/FOP and Renilla luciferase reporters, a
E6AP protein were analyzed by Western blot assay. (B–D) HEK293T cells were transfected
amounts of HPV16 E6 and E6AP (B, C) or E6 mutant (D). (E) Primary human keratinocytes s
reagent with the TOP/FOP and Renilla luciferase reporters, E6AP or pcDNA (1 μg). Wnt3a C
was evaluated 48 h posttransfection. Expression of E6HA was analyzed by Western blot. D
activation) (E) from at least three experiments are shown. A representative assay out of tcells, β-catenin staining was membrane associated. Nuclear expres-
sion of β-catenin was occasionally detected. The number of cells with
membrane or nuclear staining in the GFP-E6 and controls was similar
(Fig. 8B). Thus, consistent with the fractionation studies, E6 did not
cause major changes in the subcellular localization of β-catenin.
HPV16 E6 enhancement of TCF/β-catenin transcription depends on E6AP
and activity of the proteasome system
Previous studies indicated that E6AP is involved in mediating
many E6 functions that impact on the global transcriptional program
of HPV-positive cell lines (Kelley et al., 2005; Beaudenon and
Huibregtse, 2008). Activation of telomerase by HPV16 E6 was
reported to depend on E6AP (Gewin et al., 2004; Liu et al., 2005;
James et al., 2006). To evaluate the role of E6AP in the E6 mediated
augmentation of the TCF-dependent transcription, we tested the
ability of E6 to enhance TCF reporter activity in U2OS cells expressing
inducible E6AP shRNA (Fig. 9). The shRNA in these cells was induced
by pretreatment with 0.2 μg/ml doxycycline for 72 h. Luciferase
reporter assays indicated the ability of E6 to augment Wnt induced
luciferase activity in doxycycline-untreated U2OS cells. However, the
enhancement was signiﬁcantly reduced upon depletion of E6AP in
cells treated with doxycycline (Fig. 9A), indicating that the E6
enhancing activity depends on E6AP expression. Consistent with
these results, cotransfection of the E6AP expression vector together
with E6 into HEK293T cells increased the signal induced by Wnt3a
and E6 alone in an E6 and E6AP dose-dependent manner (Fig. 9B, C).
Moreover, reporter assays carried out with primary human keratino-
cytes stably transduced with HPV16 E6HA or vector indicated thatressing inducible shE6AP were either treated or not treated with doxycycline for 72 h.
nd increasing amounts of E6. Luciferase activity was measured after 48 h. The levels of
with DNA of Wnt3a, HFz1, the TOP/FOP luciferase reporter, β-gal and the indicated
tably transduced with 16E6HA or vector were transfected using the jetPEI transfection
M or control L medium was added 24 h after transfection. Luciferase reporter activity
ata representing average and SD of fold activation (C, D) or luciferase activity (signal
wo is shown in B.
54 H. Lichtig et al. / Virology 396 (2010) 47–58treatment with Wnt3a CM induced moderate signaling response that
was about 2-fold higher in the E6 expressing cells. Cotransfection of
E6AP caused marked elevation of the reporter signal in the E6
expressing cells with only small increase in the vector control, thus
indicating the requirement of the E6/E6AP complex for augmentation
of the Wnt signal in human keratinocytes (Fig. 9E).
In further assays using HEK293T cells, we tested the activity of E6
mutants. Functional analysis of E6 mutants previously characterized
for their ability to interact with E6AP (Liu et al., 1999; Sekaric et al.,
2008) indicated that mutant F2V, identiﬁed as capable of association
with E6AP, was able to enhance Wnt3a induced transcription,
whereas mutants L110Q and G130V, identiﬁed as defective in E6AP
binding capacity, showed signiﬁcantly reduced ability to enhance
TCF/β-catenin transcription (Fig. 9D). These results further support
the requirement of E6AP in the E6 mediated enhancement of TCF/β-
catenin transcription.
As E6/E6AP complex acts in the ubiquitination of certain cellular
proteins that are subsequently targeted to proteasomal degradation,
we investigated whether E6/E6APmediated enhancement of theWnt
signal depends on the activity of the proteasome. HEK293T cells were
transfected with plasmids encoding the E6 and E6AP proteins. Cells
were treated with Wnt3a CM and 2 μM MG132 or DMSO (Fig. 10). In
the DMSO-treated control cellsWnt3a induced signiﬁcant elevation in
the reporter activity which was further augmented by E6, E6AP, and
most prominently, E6 and E6AP. An increase in the transcription
signal, up to 20-fold above the signal induced by Wnt, was
demonstrated (Fig. 10A). Wnt3a also increased the protein levels of
β-catenin with no further ampliﬁcation upon addition of E6, E6A orFig. 10. Enhancement of the TCF/β-catenin-dependent transcription by HPV16 E6
depends on the proteasome activity. (A) HEK293T cells were transfected with the TCF-
luciferase reporter, β-gal, and E6 (0.5 μg) or/and E6AP (1 μg) as indicated. At 24 h after
transfection cells were treated with Wnt3a CM. At the same time MG132 (2 μM) or
DMSO was added to the medium. Luciferase reporter activity was measured 48
h posttransfection. Average and SD of at least three experiments are shown. (B) 100 μg
from the total cell lysates were analyzed by Western blot. β-Catenin levels were
detected with the anti-β-catenin antibody. Actin was used as a loading control.both (Fig. 10B). Treatment of cells with the proteasome inhibitor
MG132 induced high Wnt signal response that was slightly elevated
in cells treated with the Wnt3a CM (Fig. 10A). Signal induction by
MG132 was associated with an elevation in the levels of the β-catenin
protein, likely due to inhibition of its proteasomal degradation
(Fig. 10B). Expression of E6, E6AP or both did not further increase
the luciferase reporter activity (Fig. 10A) or the levels of β-catenin
(Fig. 10B). These results indicated that E6/E6AP function in Wnt
signal elevation depends on the proteasome activity and is not
mediated through alteration of β-catenin levels.
Discussion
The oncogenes E6 and E7 encoded by the high-risk HPVs directly
contribute to cancer progression. A number of cellular pathways with
which these proteins interact have been elucidated already; however,
it is clear that others have yet to be identiﬁed (Zur-Hausen, 2002;
Narisawa-Saito and Kiyono, 2007). The role of the Wnt–TCF signaling
pathway in the development of cervical cancer has not been
elucidated although recent reports provide evidence on deregulation
of this pathway in cervical cancers which are associated in the
majority with HPVs (Imura et al., 2001; Shinohara et al., 2001;
Pereira-Suarez et al., 2002; Rodriguez-Sastre et al., 2005; Uren et al.,
2005; Perez-Pereira et al., 2007).
The present study demonstrates for the ﬁrst time that HPV16 E6
enhances the canonical Wnt–TCF signaling, thus providing a possible
mechanistic link between HPV and the Wnt pathway in cervical
cancers. Previous studies showed that activation of the canonical Wnt
signal in HPV immortalized keratinocytes induced their malignant
transformation while Wnt signal activation in cells absent of HPV did
not (Uren et al., 2005). E6 ability to augment Wnt signaling could be
one of the possible ways by which HPV oncoproteins may contribute
to promote transformation of human keratinocytes.
Reporter assays described herein indicated that HPV16 E6 by itself
could not induce TCF-β-catenin-dependent transcription, however,
expression of E6 in cells where Wnt signal was induced by treatment
with Wnt3a CM, transfection of HFz1 and Wnt3a or transfection of β-
catenin, resulted in a dose-dependent enhancement of the Wnt-
induced signal. This activity was exhibited by the high-risk HPV16 E6
and to a lower extent, by HPV18 E6, but only minimally by the low-
risk HPV11 E6. The enhancement was speciﬁc to the TCF-dependent
promoter as indicated by the minimal signal values induced upon
transfection of the mutated TCF-luciferase plasmid (FOP) and by the
inhibitory effect of the plasmid encoding a TCF-dominant negative
protein, whose expression abolished signal activation as well as
enhancement by E6. Induction of theWnt signal and its augmentation
by HPV16 E6 was reproduced in various cell types, including human
epithelial cells from the cervix (C33A cervical carcinoma cell line) and
primary foreskin keratinocytes the target cells of HPV infection. E6
activity was evidenced using artiﬁcial as well as native (cyclin D1)
TCF-dependent promoter constructs. HPV16 E6 also increased cyclin
D1 protein levels in cells where Wnt signal was induced (data not
shown). Consistent with this ﬁnding high levels of cyclin D1
expression were observed in cervical carcinoma cell lines containing
HPV (Fig. 2). These results are in agreement with a recent report
demonstrating an association between cytoplasmic and nuclear
expression of cyclin D1 and presence of HPV in premalignant lesions
and cervical cancer (Carreras et al., 2007).
Numerous studies have shown that the Wnt signaling pathway is
activated in virally associated cancers, including cancers induced by
herpes and hepatitis viruses (reviewed in Hayward et al., 2006;
Levrero, 2006). Various viral oncoproteins were shown to activate
Wnt signaling through stabilization of β-catenin using different
mechanisms (Hayward et al., 2006; Levrero, 2006). Results of epitasis
experiments presented herein, based on TCF-luciferase reporter
assays, suggested that E6 acts downstream of the GSK3β/APC/Axin
55H. Lichtig et al. / Virology 396 (2010) 47–58degradation complex and that its enhancing effect may not be
associated with β-catenin stabilization. HPV16 E6 induced a similar
boost inWnt signal in cells where GSK3β activity was inhibited by LiCl
or in cells transfectedwith amutantβ-catenin resistant to GSK3β/APC
complex induced phosphorylation. In addition, signal enhancement by
E6was exhibited in colon carcinoma cell lines containingmutated APC
or β-catenin, refractory to GSK3β induced phosphorylation (Figs. 4
and 5). Additional results gathered from coexpression and half-life
determination assays indicated that E6 also did not signiﬁcantly alter
the expression levels or stability of β-catenin (Fig. 6).
β-Catenin is presented in cells in two pools exerting different
functions. The membrane E-cadherin-bound β-catenin is involved in
cell–cell adhesion whereas the cytoplasmic β-catenin is transported
to the nucleus to activateWnt target genes (Lustig and Behrens, 2003;
Giles et al., 2003; Kikuchi, 2003; Clevers, 2006). As HPV16 E6 was
previously shown to reduce the levels of E-cadherin in primary
keratinocytes (Matthews et al., 2003), we assumed that E6 may alter
the cellular distribution of β-catenin. However, results from our
fractionation experiments with transfected HEK293T cells (Fig. 7) and
immunoﬂuorescence assays using HCT116 colon carcinoma cells
(Fig. 8) did not support this assumption. We observed no major
alteration in the soluble cytoplasmic or nuclear levels of β-catenin
(Fig. 7) nor did we detect alteration in the ratios of membrane/
nuclear staining of β-catenin in E6 expressing cells (Fig. 8). Thus, our
studies indicate that different from mechanisms attributed to herpes,
polyoma and hepatitis virus oncoproteins (Hayward et al., 2006; Gan
and Khalili, 2004; Levrero, 2006), upregulation of β-catenin and its
relocation to the nucleus may not be involved in the HPV16 E6
mediated enhancement of TCF-β-catenin transcription.
The mechanism by which HPV16 E6 promotes Wnt signaling
needs further investigation. However, data presented herein indicate
that this mechanism is independent from p53 and from the PDZ-
containing E6 targets (reviewed in Mammas et al., 2008; Howie et al.,
2009). Augmentation of the Wnt signal was clearly demonstrated by
an HPV16 E6 truncation mutant (M141), which lacks the PDZ binding
domain and could be reproduced by E6 in cell lines lacking p53
(H1299) or in cells where p53 activity is compromised (C33A, SW480,
Colo32). Results from analysis of a series of HPV16 E6 mutants (Fig. 3)
further supported this notion, indicating that the ability of E6 to
induce degradation of p53 is insufﬁcient for signal activation.
Our data point, however, to the requirement of the E3 ubiquitin
ligase E6AP and the activity of the proteasome system for the E6
transcriptional function. Augmentation by E6 could not be induced in
U2OS cells where E6AP was depleted by shE6AP expression or by E6
mutants defective for the E6AP binding function (Fig. 9). Moreover,
coexpression of E6AP and E6 induced much higher increase of the
Wnt signal, activity which was completely abolished in cells where
the proteasome system was inhibited by MG132 (Fig. 10). Difference
in E6AP binding could also explain the differences observed among E6
proteins of various HPV types in augmentation of the Wnt signal
(Fig. 1F). HPV16 E6 that exhibited the highest ability to augment Wnt
signaling was shown to bind more strongly to E6AP as compared to
HPV18, whereas HPV11 has only minimal levels of binding to E6AP
(reviewed in Howie et al., 2009). E6AP is hijacked by E6 to target
several proteins for ubiquitin-dependent degradation. Known sub-
strates of the E6/E6AP complex include the tumor suppressor p53,
several PDZ domain proteins, E6 TPi, MCM7, Bak and the transcrip-
tional repressor of hTERT gene expression, NFX1-91 (reviewed in
Beaudenon and Huibregtse, 2008; Howie et al., 2009). The level of
NFX1-91 is reduced in HPV16 E6 expressing cells as well as its
occupancy at the hTERT promoter (Gewin et al., 2004; Xu et al., 2008).
Thus, E6/E6AP could activate the Wnt pathway by targeting a yet
unidentiﬁed regulator that suppressesWnt signaling in the cytoplasm
or more likely, in the nucleus. Known transcriptional corepressors for
Wnt transactivation include the C-terminal-binding protein (ctBP),
Groucho/TLE1 and the 9-kDa inhibitor of β-catenin and Tcf-4 (ICAT;Willert and Jones, 2006). Other chromatin remodeling complexes
counteracting Wnt signaling were also described (Mosimann et al.,
2009). In addition, several central cytosolic Wnt regulators including,
APC, Axin, GSK3β and Dsh also localize to the nucleus where theymay
directly or indirectly interact with β-catenin and modulate its
transcriptional activity (Willert and Jones, 2006).
Additional studies are needed to determine whether E6/E6AP
proteins alter the assembly of transcription complexes on β-catenin/
TCF promoters, whether they modify acetylation of promoter-bound




PCEV29/HFz1 and Wnt3a cloned in pLNCX vector were described
previously (Gazit et al., 1999). Cloning of the Myc-tagged β-catenin
and Myc-tagged constitutively active S33Y mutant β-catenin (pCCB/
β-catenin S33Y-Myc) was described previously (Golan et al., 2004).
The Wnt responsive TCF-dependent luciferase construct, superTOP-
FLASH and its mutated version superFOPFLASH (also named Super8-
xTOPFlash and Super8xFOPﬂash) are based on the original TOPFLASH
and FOPFLASH plasmids from Hans Clevers laboratory (Korinek et al.,
1997). However, these plasmids contain eight TCF/ β-catenin binding
sites (superTOPFLASH) or mutated TCF-binding sites (superFOP-
FLASH) upstream from the promoter (minimal TK) that drives the
expression of the Fireﬂy luciferase gene (Veeman et al., 2003). The
plasmids pCMV-Renilla (Promega) and pCMV/β-galactosidase (β-gal;
Clontech) were purchased from the indicated companies and used to
evaluate the efﬁciency of transfection. The cyclin D1 luciferase
reporter (Cyclin D1/Luc), harboring the β-catenin/TCF response
element, kindly provided by Dr. C. Albanese (Georgetown University
Medical Center), was described previously (Golan et al., 2004).
Expression plasmids encoding the HPV16 E6, E7, epitope-tagged E6
and E6 carboxy-terminal deletion mutants, all cloned in the pJS55
vector, were described previously (Sherman and Schlegel, 1996;
Sherman et al., 2002).These plasmids were used in most experiments
described herein. DNAs encoding the native forms of HPV18 E6,
HPV11 E6 and HPV16 E6 (kindly provided by Dr. M. Tommasino)were
excised from the pSP64 vector and cloned into the EcoRI and HindIII
sites of pcDNA 3.1. The HPV16 GFP-E6 expression plasmid was
constructed by excision of the E6wt coding region from the pJS55
vector using the restriction enzymes XhoI and HindIII and insertion in
frame into the pEGFP-C3 vector (Clontech) cut with the same
enzymes. The pcDNA/ΔTCF-HA plasmid encoding a dominant-
negative TCF was a gift from Dr. A. Gazit (Department of Human
Microbiology, Tel Aviv University). The HPV16 E6 mutants G130V,
L110Q, F2V, cloned in LXSN vector, were described previously (Sekaric
et al., 2008). The mutant E6 genes were recloned into the pJS-55
vector in the EcoRI and BamHI sites. The pcDNA3-HA-E6AP vector was
kindly provided by Dr. Scheffner (Department of Biology, University of
Konstanz).
Cell cultures, transfections and retroviral infections
Human embryonic kidney cells, HEK293T, colon carcinoma cell
lines, HCT116, SW480, Colo320, cervical carcinoma cell lines, C33A,
CaSki, SiHa, HeLa, the lung adenocarcinoma cell line, H1299, the
osteosarcoma cell line, U2OS, the Wnt3a-secreting L cells and control
L cells (ATCC) were cultured in DMEM supplemented with 10% fetal
calf serum. Primary human keratinocytes obtained from neonatal
foreskin explants were grown in keratinocyte serum-free medium
(KSFM) supplemented with 5 ng/ml epidermal growth factor (EGF)
and 50 μg/ml bovine pituitary extract (BPE; Invitrogen). For
preparation of Wnt3a conditioned medium (Wnt3a CM), Wnt3a-
56 H. Lichtig et al. / Virology 396 (2010) 47–58secreting L cells were cultured for 4 days, then medium was removed
and fresh medium was added for another 3 days. Medium was
harvested and sterilized using a 0.22-μm ﬁlter. Medium from L cells
was used as control. Cells were transfected by a modiﬁed calcium
phosphate procedure as described previously (Sherman and Schlegel,
1996) or by using the jetPEI reagent (polyPlus Transfection). Stable
transduction of C33A cervical cancer cells or primary keratinocytes
(PHKs) with retroviruses carrying the HPV16 E6 gene and selection in
G418 (Geneticin) was carried out as previously described (Alfandari
et al., 1999). Expression of the transduced genes was conﬁrmed by RT-
PCR with the appropriate E6 primers or by Western blot.
Luciferase reporter activity assay
Cells growing in 5 cm or six-well dishes were transfected at 60–70%
conﬂuence with DNA of the superTOPFLASH or the control super-
FOPFLASH (containing mutated TCF/β-catenin binding sites; 1 μg)
plasmid, the β-gal (0.1 μg) or Renilla luciferase (0.5 μg) expression
plasmid (used to evaluate the transfection efﬁciency) and various
amounts of the E6plasmid (as indicated).Wnt signalingwas inducedby
either cotransfection of the plasmids encoding theWnt ligand, pWnt3a
(0.1 μg), and the Wnt receptor, human frizzled 1, pHFz1 (0.3 μg),
transfection of a β-catenin encoding plasmid (1 μg), or treatment with
Wnt3a CM for 24 h prior to cell extraction. LiCl induced signal was
achieved by treating the cells with 33 mM LiCl for 24 h. Empty vector
DNA was added to adjust for equal amounts of transfected DNA. Forty-
eight hours after transfection, luciferase levelsweremeasuredusing the
Luciferase Assay System kit (Promega). The Fireﬂy luciferase activity
was normalized relative to the β-galactosidase or Renilla luciferase
activity, as described previously (Sherman et al., 2002; Lichig et al.,
2006). Luciferase readouts obtained with the superFOPFLASH control
plasmid were exceedingly low (0.01–0.001 of the superTOPFLASH
signal) and were subtracted from the readouts obtained with the
superTOPFLASH plasmid. Data are presented as luciferase readouts
(luciferase activity) or as relative luciferase readouts (fold activation)
compared between E6 and vector expressing cells, where luciferase
readouts in the vector cells were presented as 1. The collated results of
fold activation are mean values and standard deviations (SD) from at
least three independent experiments done in duplicates.
Subcellular fractionation
To prepare the soluble-cytoplasmic fraction, cells were lysed in a
solution of 50 mM Hepes pH 7.0, 250 mM NaCl, 0.1% NP40 and 1%
aprotonin. Extracts were clariﬁed by centrifugation at 13,000 rpm for
2 min and the supernatant was used (Massimi et al., 2006). Nuclear
fractions were prepared as described previously (Dignam et al., 1983).
293T cells were washed in ice-cold phosphate-buffered saline and
resuspended in cold buffer containing 10 mM HEPES pH 7.9, 10 mM
KCl, 1 mM dithiothreitol, 0.1 mM EGTA, 0.1 mM EDTA and protease
inhibitor cocktail (Sigma). Resuspended cells were lysed in 0.5%
Nonidet P-40 for 15 min followed by centrifugation at 1000 × g for 5
min. Following separation of the cytoplasmic fraction, the nuclei were
harvested by resuspension in ice-cold buffer (20 mM HEPES, pH 7.9,
0.4 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 1mM EGTA and
protease inhibitor cocktail) followed by centrifugation at 13,000 rpm
for 15 min at 4 °C.
Western blot analysis
Total cell lysates were prepared using the lysis buffer provided in
the Luciferase Assay System kit (Promega). Electrophoresis on
polyacrylamide gels, transfer to nitrocellulose membranes and
reaction with antibodies was carried out as described previously
(Alfandari et al., 1999; Lichig et al., 2006). Filters were cut into strips,
blocked with 5% low fat milk and then incubated with the speciﬁcantibodies. Membraneswere salinewashed and incubated for 1 hwith
the secondary antibody at 4 °C. After washing in Tween/phosphate-
buffered saline, membranes were subjected to enhanced chemilumi-
nescence detection analysis (Biological Industries) using horseradish
peroxidase-conjugated secondary antibodies. Primary antibodies used
were as follows: anti-β-catenin (mouse, E-5, sc-7963), anti-cyclin D1
(mouse, 72-13G, sc-450), anti-p53 (mouse, DO-1, sc-126) and anti-
histone (rabbit, FL-219, sc-10806) all from Santa Cruz Biotechnology;
anti-actin (mouse, AC-15, A5441 ) and anti-tubulin (mouse, B-5-1-2,
T5168) from Sigma; anti-HA (rat, 1 867 423) and anti-GFP (mouse,
11814460001) from Roche; anti-active-β-catenin (anti-ABC) clone
8E7mousemonoclonal antibody (05-665) fromUpstate Cell Signaling
Solution. Secondary antibodies used: anti-mouse, anti-rat and anti-
rabbit conjugated to horseradish peroxidase from Jackson Immuno
Research Laboratories.
Immunoﬂuorescence staining
HCT116 cells grown on glass coverslips were transfected with the
GFP or the HPV16 GFP-E6 expression plasmid. At 48 h after
transfection cells were washed with phosphate-buffered saline
(PBS) and ﬁxed with 4% paraformaldehyde for 20 min. After washing
with PBS cells were permeabilized with 0.1% Triton X-100 for 30 min
and incubated in 1% BSA solution for 1 h. Cells were stained with the
primary anti-β-catenin antibody (E-5, sc-7963) diluted 1/100 for 2 h,
followed by 1 h staining with the secondary antibody conjugated to
rhodamine (mouse-Jackson Immuno Research Laboratories) diluted
1/500. Cells were also stained with DAPI (0.004%) and visualized
using confocal microscopy system (LSM-510 Carl-Zeiss).
Generation of U2OS cells stably transduced with shE6AP
Plasmids for the lentivirus vector-mediated drug-inducible RNA
interference system (pLVTHM, ptTR-KRAB-Red) and cloning of
oligonucleotides for E6AP shRNA were described previously (Louria-
Hayon et al., 2009). For the production of lentiviral particles, HEK293T
cells were transfected with ptTR-KRAB-Red and pLVTHM-shE6AP
plasmids (10 μg) together with pCMV-R8.91 (packaging construct;
6.5 μg) and pMD2.VSVG (envelop construct; 3.5 μg) in 10 cm dishes
using 2mg/ml PEI (polyethylenimine, Sigma). Collection of the virus
from cell supernatants was carried out 40 h after transfection. Virus
containing medium from seven transfected HEK293T 10-cm dishes
was concentrated to 1 ml by centrifugation at 70,000 × g and
concentrated virus was used to infect U2OS cells in the presence of
polybrene (8 μg/ml). Two days later, the cells were seeded and
doxycycline (DOX) was added to half of the cells at a ﬁnal
concentration of 0.2 μg/ml. Four days later the cells were harvested
and analyzed for E6AP protein expression by Western blot.
Statistical analysis
Data of activity in the various functional assays are presented in
the ﬁgures as average (mean) values±SD. Data were subjected to a
one-way ANOVA. Signiﬁcance was accepted at Pb0.05.
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